Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
暂无分享,去创建一个
In 2014, the FDA approved two drugs for idiopathic pulmonary fibrosis that posed a regulatory challenge: the primary efficacy variable studied was the change in forced vital capacity, which hadn't been established as a surrogate for clinically meaningful benefit.
[1] A. Montgomery,et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. , 2013, American journal of respiratory and critical care medicine.
[2] Benjamin D. Sommers,et al. Reasons for the wide variation in Medicaid participation rates among states hold lessons for coverage expansion in 2014. , 2012, Health affairs.
[3] H. Collard,et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.